Federal Register Notice: FDA is making available a draft guidance for industry entitled Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection. It defines, by way of example, the circumstances that FDA would consider to constitute delaying, denying, etc. an entry or inspection for the purposes of making a drug adulterated. To download this guidance, click here. To view this notice, click here.
